Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ajay O. Mehta"'
Autor:
Garrick Kassab, José Baselga, Alvaro Moreno-Aspitia, Otto Metzger Filho, Richard D. Gelber, David W. Hillman, Kamal S Saini, Christine Campbell, Ann E. McCullough, Larissa A. Korde, Antonio C. Wolff, Masakazu Toi, Kathleen I. Pritchard, Miguel Izquierdo, Zeba Aziz, Daniela Dornelles Rosa, Frances M. Boyle, Ian E. Smith, Celine Schurmans, Georgia Demetriou, István Láng, Michael Untch, Binghe Xu, Zhimin Shao, Eileen Holmes, Evandro de Azambuja, Carlos Barrios, Eleanor McFadden, Martin Andersson, Martine Piccart-Gebhart, Debora Fumagalli, Sung Hoon Sim, Robin McConnell, Christian Jackisch, Ajay O. Mehta, Sarra El-Abed, Vicki Paterson, Emma Paterson, Florentine Hilbers, Michael S. Ewer, Vasiliki Balta, Sebastien Guillaume
Publikováno v:
Eur J Cancer
Aim To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial. Patients and methods 8381 patients with stage I-III HER2 positive breast cancer randomised to chemotherapy plus 1-year of trastuzumab (T), oral lapatinib (L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0e9f5c8f17b4247bc217c5b44068a00
https://pubmed.ncbi.nlm.nih.gov/33765513
https://pubmed.ncbi.nlm.nih.gov/33765513
Autor:
Julie R. Gralow, Ajay O. Mehta, L. P. Briley, Lyndsay Harris, L. Warren, E. A. Perez, Georgia Demetriou, Julie Byrne, Masakazu Toi, Colin F. Spraggs, Martine Piccart, JoAnne Zujewski, Zeba Aziz, A Armour, S. Ahmed, Martin Andersson, Laura R. Parham, L. S. Williams, Z-f Jiang, N. Jackson, R. Crescenzo, D. J. Fraser
Publikováno v:
The Pharmacogenomics Journal. 18:480-486
HLA-DRB1*07:01 allele carriage was characterised as a risk biomarker for lapatinib-induced liver injury in a large global study evaluating lapatinib, alone and in combination with trastuzumab and taxanes, as adjuvant therapy for advanced breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130dedd979d5def9101526c0373bb0b0
https://doi.org/10.1038/tpj.2017.39
https://doi.org/10.1038/tpj.2017.39
Autor:
Robert Petit, Partha Basu, Subhashini John, Minish Mahendra Jain, Sudeep Gupta, Rajnish V. Nagarkar, Ajay O. Mehta
Publikováno v:
International Journal of Gynecological Cancer
Supplemental digital content is available in the text.
Objectives A global unmet medical need exists for effective treatments for persistent, recurrent, or metastatic cervical cancer, as patients have a short life expectancy. Recently, immunothe
Objectives A global unmet medical need exists for effective treatments for persistent, recurrent, or metastatic cervical cancer, as patients have a short life expectancy. Recently, immunothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba19380712550a0b7bbaeb412704a00d
https://pubmed.ncbi.nlm.nih.gov/29538258
https://pubmed.ncbi.nlm.nih.gov/29538258
Autor:
Suryanarayan Deo, Ramon Colomer, Sung Bae Kim, Soo-Chin Lee, Ajay O. Mehta, Bin Yao, Igor Bondarenko, Ron Bose, Chanchal Goswami, Lisa A. Carey, Feng Xu, Georgia Demetriou, Rajendra A. Badwe, Kenichi Inoue, Thomas Bachelot, Ahmad Awada, Alvin Wong, Richard Bryce
Importance Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed. Objective To determine whether neratinib, an irreversible pan-ERBB tyrosine kinase inhibitor, plus paclitaxel improves
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90b13e12b4a93d6aa9fc5af99ad2b430
Autor:
Rajesh Cn, Ateeq Ahmad, Rajnish Nagarkar, Suraj Pawar, Anup Majumdar, Tanveer Maksud, Shoukath M. Ali, Imran Ahmad, Satish Ramkrishna Sonawane, Ajay O. Mehta, Hanmant Barkate, Jitendra Singh, Srinivasan Krishnan, Satish Kamath, Kalyan Kusum Mukherjee, Shanti P Shrivastav, Chiradoni T Satheesh, Saifuddin Sheikh, Mahesh Paithankar
Publikováno v:
Journal of Cancer Science and Therapy.
Lung cancer is one of the most common causes of cancer-related death in men and women throughout the world. An appropriate statistical model for survival analysis on lung cancer can provide precise prognosis for treatment planning. Usually the tradit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::859be187bc4c227999663dc80fd0c09c
https://doi.org/10.4172/1948-5956.1000334
https://doi.org/10.4172/1948-5956.1000334
Autor:
Ron Bose, Soo-Chin Lee, Chanchal Goswami, Kenichi Inoue, Lisa A. Carey, Svs Deo, Ajay O. Mehta, Alvin Wong, Georgia Demetriou, Feng Xu, Thomas Bachelot, Ramon Colomer, Richard A. Bryce, Igor Bondarenko, Xiaojia Wang, Rajendra A. Badwe, Ahmad Awada, Vitaly Smirnov, Zhen-Zhou Shen, Sung Bae Kim
Publikováno v:
Journal of Clinical Oncology. 33:610-610
610 Background: This large randomized open-label phase 2 trial compared the efficacy and safety of Neratinib (N), the irreversible pan-HER tyrosine kinase inhibitor, + Paclitaxel (P) vs Trastuzumab...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f593ef5dc4b086abc2f73047dcc0a3d2
https://doi.org/10.1200/jco.2015.33.15_suppl.610
https://doi.org/10.1200/jco.2015.33.15_suppl.610
Autor:
Julie Byrne, Colin F. Spraggs, L. S. Williams, Julie R. Gralow, Zeba Aziz, A Armour, Zhongsheng Tong, Masakazu Toi, Liling Warren, Ajay O. Mehta, L. P. Briley, Zefei Jiang, Nicola Jackson, Lyndsay Harris, Rocco Crescenzo, Shun D. Moodley, Martin Andersson, Dana Fraser, Laura R. Parham
Publikováno v:
Journal of Clinical Oncology. 33:617-617
617 Background: ALTTO (NCT00490139) is a large adjuvant breast cancer (ABC) study evaluating lapatinib, alone and in combinations with trastuzumab and taxanes. Characterization of hepatic abnormali...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae7f9334a4b01229b5ac9d56a332a2af
https://doi.org/10.1200/jco.2015.33.15_suppl.617
https://doi.org/10.1200/jco.2015.33.15_suppl.617
Autor:
Sudeep Gupta, Minish Mahendra Jain, Robert Petit, Ajay O. Mehta, Rajnish Nagarkar, Vijay Kumar, Partha Basu, Rakesh Neve, Subhashini John, Sumana Premkumar
Publikováno v:
Journal of Clinical Oncology. 32:5610-5610
5610 Background: ADXS11-001 immunotherapy is a live attenuated Listeria monocytogenes (Lm) bioengineered to secrete a HPV-16-E7 fusion protein targeting HPV transformed cells. The Lm vector serves ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17d26a8e4b5804603c7e20eaeac07038
https://doi.org/10.1200/jco.2014.32.15_suppl.5610
https://doi.org/10.1200/jco.2014.32.15_suppl.5610
Autor:
R. C. Rane, Imran Ahmad, Ajay O. Mehta, Suraj Pawar, Satish Ramkrishna Sonawane, Krishnan Srinivasan, Jitendra Singh, Anup Majumdar, Tanveer Maksud, SP Shrivastav, Rajnish Nagarkar, Satish V Kamat, Kalyan Kusum Mukherjee, Ateeq Ahmad, C T. Satheesh, Saifuddin Sheikh, Manish R. Sharma
Publikováno v:
Journal of Clinical Oncology. 32:573-573
573 Background: The primary reason for the development of Lipid Based formulation of Paclitaxel is to improve the drug’s safety profile by eliminating Cremophor EL (CrEL) and ethanol from Paclitaxe...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13fc031e42b128b061bc2c980a12280c
https://doi.org/10.1200/jco.2014.32.15_suppl.573
https://doi.org/10.1200/jco.2014.32.15_suppl.573
Autor:
Martina Uttenreuther-Fischer, Tamas Hickish, Chiun-Sheng Huang, Nadezhda V. Kovalenko, Dmitry P. Udovitsa, K Pelling, Janice Tsang, Ling-Ming Tseng, Ajay O. Mehta
Publikováno v:
Journal of Clinical Oncology. 30:TPS651-TPS651
TPS651 Background: Management of HER2-overexpressing MBC has improved over the past decade. However, pts still develop resistance to currently available HER2-targeted therapies and novel effective treatments are increasingly required as dual targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e43145026339476c7fa714b4c7926304
https://doi.org/10.1200/jco.2012.30.15_suppl.tps651
https://doi.org/10.1200/jco.2012.30.15_suppl.tps651